In the BioHarmony Drug Report Database

"Preview" Icon

Lisdexamfetamine dimesylate

Vyvanse (lisdexamfetamine dimesylate) is a small molecule pharmaceutical. Lisdexamfetamine dimesylate was first approved as Vyvanse on 2007-02-23. It is used to treat attention deficit disorder with hyperactivity and binge drinking in the USA. Vyvanse’s patent is valid until 2023-02-24 (FDA).

 

Trade Name

 

Vyvanse
 

Common Name

 

lisdexamfetamine dimesylate
 

ChEMBL ID

 

CHEMBL1201178
 

Indication

 

attention deficit disorder with hyperactivity, binge drinking
 

Drug Class

 

Amfetamine derivatives

Image (chem structure or protein)

Lisdexamfetamine dimesylate structure rendering